A forum for researchers, students and applicants in the field of cyclodextrin technology
Roquette {oosts Extensive Cyclodextrins Portfolio with Launch of KLEPTOSE® Crysmeb Methyl-Beta-Cyclodextrin for Oral and Parenteral Formulations In contrast to DIMEB
This workshop is part of the NextNano4Cancer project, funded under the ERA4Health Joint Transnational Call “Nano and advanced technologies for
Hungarian Society of Experimental and Clinical Pharmacology (HUPHAR) will host its annual conference, “HUPHAR2026 International Conference of Pharmacology, Drug Research
All these studies utilize the high solubilizing effect of 2,6-di-O-methyl beta-cyclodextrin studying various model drugs. The compatibility, inclusion stability, and
The unique physicochemical properties of cupric oxide nanoparticles (CuO NPs) make them suitable for a wide range of therapeutic applications.
Pediatric drug development faces notable challenges due to age-related physiological differences, with limited approved formulations often leading to off-label or
Combination therapy has emerged as a promising strategy in cancer treatment, aiming to enhance therapeutic efficacy and overcome drug resistance.
The special issue is organized by Pharmaceutics, an open access journal. Guest Editors: Dr. Ademar Alves Da Silva Filho, Dr.
The review “MagnetoCyclodextrins: Synthesis, challenges, and opportunities” explores MagnetoCyclodextrins (MNP CDs), hybrid nanomaterials created by combining the magnetic properties of
Cyclodextrins (CDs) and their polymers are gaining momentum as advanced drug delivery systems. A recent review (https://www.sciencedirect.com/science/article/pii/S2590257125000203) highlights their progress
